In this issue:
Activity of venetoclax in patients with CLL
Lisocabtagene maraleucel in relapsed/refractory MCL
Maintenance and consolidation strategies for untreated advanced FL
Clinical outcomes of hypomethylating agents plus venetoclax for AML
The impact of CHOP versus bendamustine on BMD patients with indolent lymphoma
Consensus recommendations for CD3×CD20 bispecific antibody therapy
Effectiveness and safety of ibrutinib in relapsed/refractory MCL
Monsuetuzumab safety profile in patients with B-cell non-Hodgkin lymphoma
IELSG30 phase 2 trial
Neurotoxicity after CD19 CAR T-cell therapy in MCL
Please login below to download this issue (PDF)